var data={"title":"Treatment of acute decompensated heart failure in acute coronary syndromes","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of acute decompensated heart failure in acute coronary syndromes</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/contributors\" class=\"contributor contributor_credentials\">Wilson S Colucci, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/contributors\" class=\"contributor contributor_credentials\">Stephen S Gottlieb, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/contributors\" class=\"contributor contributor_credentials\">James Hoekstra, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/contributors\" class=\"contributor contributor_credentials\">Susan B Yeon, MD, JD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 27, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with acute decompensated heart failure (ADHF) often have coronary artery disease with or without an acute coronary syndrome [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/1\" class=\"abstract_t\">1</a>]. The acute onset of severe myocardial ischemia can lead to a sudden impairment in systolic and diastolic function, resulting in a decreased cardiac output, elevated filling pressures, and the development of pulmonary edema. Flash pulmonary edema can result from myocardial ischemia with or without myocardial infarction (MI).</p><p>Specific considerations apply to treatment of ADHF in patients presenting with acute coronary syndromes. The recommendations presented here are generally in agreement with those published in the 2004 American College of <span class=\"nowrap\">Cardiology/American</span> Heart Association <span class=\"nowrap\">(ACC/AHA)</span> ST elevation MI guidelines with 2007 focused update, the 2007 <span class=\"nowrap\">ACC/AHA</span> unstable <span class=\"nowrap\">angina/non-ST</span> elevation MI guideline, and the 2009 focused update of the 2005 <span class=\"nowrap\">ACC/AHA</span> HF guidelines [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/2-5\" class=\"abstract_t\">2-5</a>].</p><p>Overall management of acute coronary syndrome and acute MI (including fuller discussion of all therapies including anticoagulant and antiplatelet agents), cardiogenic shock in the setting of acute MI, and general treatment of ADHF are discussed separately. (See <a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Overview of the acute management of ST-elevation myocardial infarction&quot;</a> and <a href=\"topic.htm?path=overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;Overview of the acute management of non-ST elevation acute coronary syndromes&quot;</a> and <a href=\"topic.htm?path=prognosis-and-treatment-of-cardiogenic-shock-complicating-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction&quot;</a>.)</p><p>Management of right ventricular MI which typically presents with hypotension and clear lungs is discussed separately (see <a href=\"topic.htm?path=right-ventricular-myocardial-infarction\" class=\"medical medical_review\">&quot;Right ventricular myocardial infarction&quot;</a>).</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">REVASCULARIZATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Urgent revascularization is a major component of therapy for patients presenting with ST elevation myocardial infarction (STEMI), and is particularly important for those with heart failure (HF). Early revascularization is indicated for patients presenting with unstable <span class=\"nowrap\">angina/non-ST</span> elevation MI <span class=\"nowrap\">(UA/NSTEMI)</span> and HF. As recommended in the 2009 focused update of the 2005 American College of <span class=\"nowrap\">Cardiology/American</span> Heart Association HF guidelines, urgent cardiac catheterization and revascularization is reasonable when it is likely to prolong meaningful survival in patients with acute HF and known or suspected acute myocardial ischemia due to occlusive coronary disease, especially when there are signs and symptoms of systemic hypoperfusion [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Overview of the acute management of ST-elevation myocardial infarction&quot;</a> and <a href=\"topic.htm?path=overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;Overview of the acute management of non-ST elevation acute coronary syndromes&quot;</a> and <a href=\"topic.htm?path=coronary-angiography-and-revascularization-for-unstable-angina-or-non-st-elevation-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Coronary angiography and revascularization for unstable angina or non-ST elevation acute myocardial infarction&quot;</a> and <a href=\"topic.htm?path=acute-st-elevation-myocardial-infarction-selecting-a-reperfusion-strategy\" class=\"medical medical_review\">&quot;Acute ST elevation myocardial infarction: Selecting a reperfusion strategy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary percutaneous coronary intervention (PCI) is recommended in patients with STEMI when it can be performed within 90 minutes of first medical contact [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/2,3\" class=\"abstract_t\">2,3</a>]. In addition, it is reasonable to promptly (within 30 minutes of arrival) transfer patients with STEMI with severe HF to facilities capable of rapid revascularization.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fibrinolytic therapy is recommended for patients with STEMI when timely primary PCI cannot be performed [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/2,3\" class=\"abstract_t\">2,3</a>]. The routine performance of PCI within 3 to 24 hours after fibrinolytic therapy has been referred to as pharmacoinvasive strategy. For patients who have received fibrinolytic therapy, a strategy of coronary angiography with intent to perform PCI (or emergency coronary artery bypass graft surgery) is recommended for patients in the following clinical settings:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cardiogenic shock who are &lt;75 years of age who are candidates for revascularization</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Severe HF <span class=\"nowrap\">and/or</span> pulmonary edema </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hemodynamically compromising ventricular arrhythmias</p><p/><p class=\"bulletIndent1\">In addition, a pharmacoinvasive strategy is a reasonable option in the following settings:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cardiogenic shock with &ge;75 years of age and who are suitable candidates for revascularization</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hemodynamic instability <span class=\"nowrap\">and/or</span> persistent ischemic symptoms.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A strategy of early coronary angiography with intent to perform revascularization is indicated in certain <span class=\"nowrap\">UA/NSTEMI</span> patients (without serious comorbidities or contraindications to such procedures), including those with the following (as well as others discussed separately):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hemodynamic instability</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Refractory or recurrent angina</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Signs or symptoms of HF or new or worsening mitral regurgitation</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Reduced left ventricular systolic function (left ventricular ejection fraction &lt;40 percent)</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">MEDICAL THERAPY</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Diuretic use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diuretic (low- to intermediate-dose <a href=\"topic.htm?path=furosemide-drug-information\" class=\"drug drug_general\">furosemide</a> or <a href=\"topic.htm?path=torsemide-drug-information\" class=\"drug drug_general\">torsemide</a> or <a href=\"topic.htm?path=bumetanide-drug-information\" class=\"drug drug_general\">bumetanide</a>) should be administered to treat pulmonary congestion if there is associated volume overload. However, caution is advised to avoid unnecessary or excessive diuresis since some patients are normovolemic, particularly those without prior left ventricular dysfunction and those who have not received fluid loading.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Supplemental oxygen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As for treatment of acute decompensated heart failure, generally, supplemental oxygen should be administered to patients with myocardial infarction (MI) with arterial oxygen desaturation and assisted ventilation should be provided as needed. It is reasonable to administer oxygen to all patients with MI during the first six hours after presentation [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/2,4\" class=\"abstract_t\">2,4</a>].</p><p>For patients requiring supplemental oxygen, we suggest initial therapies in the following order:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Non-rebreather face mask delivering high-flow percent oxygen</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If respiratory distress, respiratory acidosis, <span class=\"nowrap\">and/or</span> hypoxia persist, we suggest noninvasive ventilation (NIV) as the preferred initial modality of assisted ventilation as long as the patient does not have a contraindication (<a href=\"image.htm?imageKey=PULM%2F60442\" class=\"graphic graphic_table graphicRef60442 \">table 1</a>).</p><p/><p>This approach is supported by evidence from meta-analyses and randomized trials in patients with cardiogenic pulmonary edema, indicating that NIV decreases the need for intubation and improves respiratory parameters.</p><p>In addition, a meta-analysis found that continuous positive airway pressure decreases in-hospital mortality [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/6\" class=\"abstract_t\">6</a>]. This beneficial effect on mortality was greater in trials with higher proportions of patients with ischemia or MI. These issues and conflicting data on a possible impact on mortality are discussed in detail separately. (See <a href=\"topic.htm?path=noninvasive-ventilation-in-acute-respiratory-failure-in-adults#H16\" class=\"medical medical_review\">&quot;Noninvasive ventilation in acute respiratory failure in adults&quot;, section on 'Cardiogenic pulmonary edema'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with respiratory failure who fail NIV, or do not tolerate or have contraindications to NIV (<a href=\"image.htm?imageKey=PULM%2F60442\" class=\"graphic graphic_table graphicRef60442 \">table 1</a>) should be intubated for conventional mechanical ventilation. In such patients, positive end-expiratory pressure is often useful to improve oxygenation. (See <a href=\"topic.htm?path=overview-of-mechanical-ventilation\" class=\"medical medical_review\">&quot;Overview of mechanical ventilation&quot;</a> and <a href=\"topic.htm?path=positive-end-expiratory-pressure-peep\" class=\"medical medical_review\">&quot;Positive end-expiratory pressure (PEEP)&quot;</a>.)</p><p/><p>Once initial therapy has begun, oxygen supplementation can be titrated in order to keep the patient comfortable and arterial oxygen saturation above 90 percent.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Morphine sulfate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the setting of ST elevation MI (STEMI), <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> sulfate is recommended as the analgesic of choice for ischemic pain relief provided that additional therapy is used to manage the underlying ischemia. In unstable <span class=\"nowrap\">angina/non-ST</span> elevation MI <span class=\"nowrap\">(UA/NSTEMI),</span> it is reasonable to administer morphine if there is uncontrolled ischemic pain, provided that additional therapy is used to manage the underlying ischemia. The recommendation for morphine is less strong in <span class=\"nowrap\">UA/NSTEMI</span> as compared to STEMI because observational data have raised concern about excess mortality in <span class=\"nowrap\">UA/NSTEMI</span> patients receiving morphine.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Vasodilator therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=nitroglycerin-glyceryl-trinitrate-drug-information\" class=\"drug drug_general\">Nitroglycerin</a> is recommended for MI patients to treat ischemic pain, hypertension, or pulmonary congestion unless the systolic blood pressure is &lt;100 mmHg or &ge;30 mmHg below baseline.</p><p><a href=\"topic.htm?path=nitroprusside-drug-information\" class=\"drug drug_general\">Nitroprusside</a> is often used when pronounced afterload reduction is required (as in the setting of ventricular septal rupture). However, limited data are available on the efficacy and safety of nitroprusside use in the setting of acute MI. One report suggested that nitroprusside administration after MI has an equivocal impact on mortality (worsening of mortality with early administration and improvement of mortality with later treatment) [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/7\" class=\"abstract_t\">7</a>]. The adverse effect of nitroprusside in patients with acute MI may be attributable to reflex tachycardia <span class=\"nowrap\">and/or</span> coronary steal.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Beta blocker therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although initiation of beta-blocker therapy within the first 24 hours is generally recommended for patients presenting with MI, such therapy is contraindicated in patients with signs of HF, evidence of a low output state, increased risk of cardiogenic shock, or other contraindications such as heart block or reactive airways disease.</p><p>Beta blocker therapy should be initiated before discharge for secondary prevention and continued indefinitely in all patients who have had an MI or acute coronary syndrome, unless contraindicated. For those who remain in HF throughout the hospitalization, low doses should be initiated, with gradual titration on an outpatient basis.</p><p>Beta blocker therapy in patients with MI is discussed in detail separately. (See <a href=\"topic.htm?path=acute-myocardial-infarction-role-of-beta-blocker-therapy\" class=\"medical medical_review\">&quot;Acute myocardial infarction: Role of beta blocker therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">ACE inhibitor and ARB therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initiation of an oral angiotensin converting enzyme (ACE) inhibitor is recommended in patients with an acute MI who have heart failure (HF) or systolic dysfunction (left ventricular ejection fraction [LVEF] &le;40 percent) unless the systolic blood pressure is &lt;100 mmHg or &gt;30 mmHg below baseline or there are other contraindications. Therapy should be administered orally and titrated starting with a low initial dose. It should be noted that aggressive ACE inhibitor therapy prior to percutaneous intervention for acute MI or prior to hemodynamic stabilization has been associated with an increased risk of cardiogenic shock. </p><p>ACE inhibitors should be initiated before discharge for secondary prevention and continued indefinitely in certain MI patients, including those with HF, LVEF &le;40 percent, hypertension, diabetes, or chronic kidney disease.</p><p>An angiotensin II receptor blocker (ARB) should be administered to MI patients with HF, LVEF &le;40, or hypertension who are intolerant of ACE inhibitors.</p><p>ACE inhibitor or ARB therapy should continue indefinitely. Careful blood pressure monitoring is required when using either agent. ACE inhibitor and ARB use in MI patients is discussed in detail separately. (See <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-recommendations-for-use\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Aldosterone antagonists</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Inpatient initiation of long-term aldosterone blockade (<a href=\"topic.htm?path=spironolactone-drug-information\" class=\"drug drug_general\">spironolactone</a> or <a href=\"topic.htm?path=eplerenone-drug-information\" class=\"drug drug_general\">eplerenone</a>) is recommended in post-MI patients with LVEF &le;40 and symptomatic HF <span class=\"nowrap\">and/or</span> diabetes without significant renal dysfunction (serum creatinine &le;2.5 <span class=\"nowrap\">mg/dL</span> [221 <span class=\"nowrap\">micromol/L]</span> in men and &le;2.0 <span class=\"nowrap\">mg/dL</span> [177 <span class=\"nowrap\">micromol/L]</span> in women) or hyperkalemia who are already receiving therapeutic doses of ACE inhibitor. (See <a href=\"topic.htm?path=use-of-mineralocorticoid-receptor-antagonists-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Use of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction&quot;</a> and <a href=\"topic.htm?path=treatment-of-acute-myocardial-infarction-in-diabetes-mellitus#H12\" class=\"medical medical_review\">&quot;Treatment of acute myocardial infarction in diabetes mellitus&quot;, section on 'Aldosterone antagonists'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">MANAGEMENT OF LOW OUTPUT STATES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A low output state may manifest as hypotension or preserved blood pressure with evidence of hypoperfusion and is not always accompanied by pulmonary congestion. Recommended treatments include inotropic support, intraaortic counterpulsation, revascularization, and surgical correction of mechanical complications (such as ventricular septal rupture or papillary muscle rupture). (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cardiogenic-shock-in-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction&quot;</a> and <a href=\"topic.htm?path=prognosis-and-treatment-of-cardiogenic-shock-complicating-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction&quot;</a> and <a href=\"topic.htm?path=intraaortic-balloon-pump-counterpulsation\" class=\"medical medical_review\">&quot;Intraaortic balloon pump counterpulsation&quot;</a> and <a href=\"topic.htm?path=mechanical-complications-of-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Mechanical complications of acute myocardial infarction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Inotropic agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with myocardial infarction (MI), pulmonary congestion, and marginal or low blood pressure often require circulatory support with inotropic and vasopressor agents <span class=\"nowrap\">and/or</span> intraaortic balloon counterpulsation to relieve pulmonary congestion and maintain adequate perfusion. (See <a href=\"topic.htm?path=intraaortic-balloon-pump-counterpulsation\" class=\"medical medical_review\">&quot;Intraaortic balloon pump counterpulsation&quot;</a>.)</p><p>The 2004 American College of <span class=\"nowrap\">Cardiology/American</span> Heart Association <span class=\"nowrap\">(ACC/AHA)</span> ST elevation MI (STEMI) guidelines suggest using <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> in hypotensive patients with clinical evidence of shock and using <a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">dobutamine</a> in hypotensive patients without clinical evidence of shock [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Dopamine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a> is recommended for hypotensive STEMI patients with clinical evidence of shock as noted in the 2004 <span class=\"nowrap\">ACC/AHA</span> guidelines. Its actions are complex and dose-dependent:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>At low doses of 1 to 3 <span class=\"nowrap\">microg/kg</span> per min, <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> acts primarily on dopamine-1 receptors to dilate the renal and mesenteric artery beds [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>At 3 to 10 <span class=\"nowrap\">microg/kg</span> per min, <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> also stimulates beta-1 adrenergic receptors and increases cardiac output, predominantly by increasing stroke volume with variable effects on heart rate.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>At medium-to-high doses, <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> also stimulates alpha-adrenergic receptors, producing arterial and venous constriction that may compromise systolic function and filling pressures. However, a study of 13 patients with class III or IV chronic heart failure (HF) with severe left ventricular systolic dysfunction suggested that renal arterial vasodilation and improvement in cardiac output may persist as the dopamine dose is titrated up to 10 <span class=\"nowrap\">&micro;g/kg</span> per min [<a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p><a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">Dopamine</a> should be reserved for hypotensive patients for whom an increase in arterial pressure is considered a priority. </p><p>Use of low-dose <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> in patients with acute decompensated HF (ADHF) is discussed separately. (See <a href=\"topic.htm?path=treatment-of-acute-decompensated-heart-failure-components-of-therapy#H123895781\" class=\"medical medical_review\">&quot;Treatment of acute decompensated heart failure: Components of therapy&quot;, section on 'Inotropic agents'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Dobutamine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of <a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">dobutamine</a> in ADHF is discussed separately. (See <a href=\"topic.htm?path=treatment-of-acute-decompensated-heart-failure-general-considerations\" class=\"medical medical_review\">&quot;Treatment of acute decompensated heart failure: General considerations&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H351455138\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-heart-failure-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Heart failure in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22359916\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with acute decompensated heart failure (ADHF) often have coronary artery disease with or without an acute coronary syndrome (ACS). Acute onset of myocardial ischemia with or without infarction can cause systolic or diastolic dysfunction, resulting in decreased cardiac output, elevated filling pressures, <span class=\"nowrap\">and/or</span> the development of pulmonary edema. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urgent revascularization is a major component of therapy for patients presenting with ST elevation myocardial infarction (STEMI) and is particularly important for those with HF. Early revascularization is indicated for patients presenting with unstable <span class=\"nowrap\">angina/non-ST</span> elevation myocardial infarction and HF. (See <a href=\"#H2\" class=\"local\">'Revascularization'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medical therapy of ADHF with ACS includes judicious use of diuretics, supplemental oxygen and ventilatory support as needed, and vasodilator therapy. (See <a href=\"#H3\" class=\"local\">'Medical therapy'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initiation of oral angiotensin converting enzyme inhibitor is recommended within the first 24 hours of an acute MI in patients with pulmonary congestion or a left ventricular ejection fraction &le;40 percent. Beta blocker therapy within the first 24 hours is generally recommended for patients presenting with MI but initiation should be deferred in patients with HF. Inpatient initiation of long-term aldosterone antagonist therapy is also recommended in selected patients. (See <a href=\"#H3\" class=\"local\">'Medical therapy'</a> above and <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-recommendations-for-use\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use&quot;</a> and <a href=\"topic.htm?path=use-of-mineralocorticoid-receptor-antagonists-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Use of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with MI, pulmonary congestion, and marginal or low blood pressure often require circulatory support with inotropic and vasopressor agents <span class=\"nowrap\">and/or</span> intraaortic balloon counterpulsation to relieve pulmonary congestion and maintain adequate perfusion. (See <a href=\"#H11\" class=\"local\">'Management of low output states'</a> above and <a href=\"topic.htm?path=intraaortic-balloon-pump-counterpulsation\" class=\"medical medical_review\">&quot;Intraaortic balloon pump counterpulsation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the setting of STEMI, <a href=\"topic.htm?path=dopamine-drug-information\" class=\"drug drug_general\">dopamine</a> is recommended in hypotensive patients with clinical evidence of shock and <a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">dobutamine</a> is recommended in hypotensive patients without clinical evidence of shock. (See <a href=\"#H12\" class=\"local\">'Inotropic agents'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/1\" class=\"nounderline abstract_t\">Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol 2009; 53:254.</a></li><li class=\"breakAll\">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).</li><li class=\"breakAll\">Antman, E, Hand, M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on May 02, 2008).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/4\" class=\"nounderline abstract_t\">Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/5\" class=\"nounderline abstract_t\">Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/6\" class=\"nounderline abstract_t\">Weng CL, Zhao YT, Liu QH, et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med 2010; 152:590.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/7\" class=\"nounderline abstract_t\">Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 1982; 306:1129.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-acute-decompensated-heart-failure-in-acute-coronary-syndromes/abstract/8\" class=\"nounderline abstract_t\">Elkayam U, Ng TM, Hatamizadeh P, et al. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action. Circulation 2008; 117:200.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3498 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22359916\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">REVASCULARIZATION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">MEDICAL THERAPY</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Diuretic use</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Supplemental oxygen</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Morphine sulfate</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Vasodilator therapy</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Beta blocker therapy</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">ACE inhibitor and ARB therapy</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Aldosterone antagonists</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">MANAGEMENT OF LOW OUTPUT STATES</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Inotropic agents</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- Dopamine</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Dobutamine</a></li></ul></li></ul></li><li><a href=\"#H351455138\" id=\"outline-link-H351455138\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H22359916\" id=\"outline-link-H22359916\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/3498|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/60442\" class=\"graphic graphic_table\">- Contraindications to NPPV</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-st-elevation-myocardial-infarction-selecting-a-reperfusion-strategy\" class=\"medical medical_review\">Acute ST elevation myocardial infarction: Selecting a reperfusion strategy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-myocardial-infarction-role-of-beta-blocker-therapy\" class=\"medical medical_review\">Acute myocardial infarction: Role of beta blocker therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-recommendations-for-use\" class=\"medical medical_review\">Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cardiogenic-shock-in-acute-myocardial-infarction\" class=\"medical medical_review\">Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-angiography-and-revascularization-for-unstable-angina-or-non-st-elevation-acute-myocardial-infarction\" class=\"medical medical_review\">Coronary angiography and revascularization for unstable angina or non-ST elevation acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraaortic-balloon-pump-counterpulsation\" class=\"medical medical_review\">Intraaortic balloon pump counterpulsation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanical-complications-of-acute-myocardial-infarction\" class=\"medical medical_review\">Mechanical complications of acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noninvasive-ventilation-in-acute-respiratory-failure-in-adults\" class=\"medical medical_review\">Noninvasive ventilation in acute respiratory failure in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-mechanical-ventilation\" class=\"medical medical_review\">Overview of mechanical ventilation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Overview of the acute management of ST-elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">Overview of the acute management of non-ST elevation acute coronary syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=positive-end-expiratory-pressure-peep\" class=\"medical medical_review\">Positive end-expiratory pressure (PEEP)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prognosis-and-treatment-of-cardiogenic-shock-complicating-acute-myocardial-infarction\" class=\"medical medical_review\">Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=right-ventricular-myocardial-infarction\" class=\"medical medical_review\">Right ventricular myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-heart-failure-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Heart failure in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-acute-decompensated-heart-failure-components-of-therapy\" class=\"medical medical_review\">Treatment of acute decompensated heart failure: Components of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-acute-decompensated-heart-failure-general-considerations\" class=\"medical medical_review\">Treatment of acute decompensated heart failure: General considerations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-acute-myocardial-infarction-in-diabetes-mellitus\" class=\"medical medical_review\">Treatment of acute myocardial infarction in diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-mineralocorticoid-receptor-antagonists-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Use of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction</a></li></ul></div></div>","javascript":null}